Not applicableUnknownNCT04621422
What this trial is testing
Contribution of New Generation Oxford Nanopore-type High-throughput Sequencing in the Diagnostic Strategy of Neurogenetic Diseases.
Who this might be right for
Neuro-Degenerative Disease
University Hospital, Bordeaux 60